title: Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).
abstract: Mammalian target of rapamycin inhibitor (mTOR-I)/proliferation signal inhibitors (PSI) including sirolimus and everolimus represent a new class of drugs increasingly used in solid-organ transplantation as alternatives to calcineurin inhibitors for patients with renal dysfunction, transplant coronary arterial vasculopathy or malignancy. The most frequently occurring mTOR-I/PSI-related adverse events are similar to those associated with other immunosuppressive therapies, but some side effects are more characteristic of proliferation signal inhibitors (e.g. lymphocele, arthralgia, oedema and hyperlipidaemia). The present paper review incidence, clinical presentation and mechanism of oedema within the clinical experience of mTOR-I/PSI in solid organ transplantation.
authors: Department of Nephrology , Pitié Salpetriere Hospital , Paris , France.
authors: Chems
authors: C
authors: Gharbi
authors: Department of Nephrology , Pitié Salpetriere Hospital , Paris , France.
authors: Victor
authors: V
authors: Gueutin
authors: Department of Nephrology , Pitié Salpetriere Hospital , Paris , France.
authors: Hassan
authors: H
authors: Izzedine
keywords: VEGF-C; angio-oedema; everolimus; lymphoedema; oedema; proliferation signal inhibitor; sirolimus